Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Schultz-Fademrecht

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Angewandte Chemie (International Ed. in English)|August 24, 2017
Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell-based Compound Discovery and Target PredictionLea Kremer, Carsten Schultz-Fademrecht, Matthias Baumann, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2008
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitorsPhilip Jones, Matthew J Bottomley, Andrea Carfí, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cellsFederica Ferrigno, Danila Branca, Olaf Kinzel, et al.
ACS Chemical Biology|July 13, 2026
Clickable Substrate Transport (CST): A High-Throughput Functional Assay for Solute Carrier ProteinsAbigail L Macmillan-Jones, Phillip Biallas, Linda Kitching, et al.
Scientific Reports|March 11, 2017
New insights into the intracellular distribution pattern of cationic amphiphilic drugsMagdalena Vater, Leonhard Möckl, Vanessa Gormanns, et al.
Journal of Medicinal Chemistry|November 6, 2009
Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapyJesus M Ontoria, Sergio Altamura, Annalise Di Marco, et al.
Oncotarget|June 15, 2018
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemiaJoachim R Göthert, Roze Imsak, Michael Möllmann, et al.
Journal of Medicinal Chemistry|June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound designAndré Richters, Julia Ketzer, Matthäus Getlik, et al.
Angewandte Chemie (International Ed. in English)|January 21, 2017
A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2Pablo Martín-Gago, Eyad K Fansa, Christian H Klein, et al.
Journal of Medicinal Chemistry|August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor ReceptorJulian Engel, Steven Smith, Jonas Lategahn, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Angewandte Chemie (International Ed. in English)|August 24, 2017
Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell-based Compound Discovery and Target PredictionLea Kremer, Carsten Schultz-Fademrecht, Matthias Baumann, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2008
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitorsPhilip Jones, Matthew J Bottomley, Andrea Carfí, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cellsFederica Ferrigno, Danila Branca, Olaf Kinzel, et al.
ACS Chemical Biology|July 13, 2026
Clickable Substrate Transport (CST): A High-Throughput Functional Assay for Solute Carrier ProteinsAbigail L Macmillan-Jones, Phillip Biallas, Linda Kitching, et al.
Scientific Reports|March 11, 2017
New insights into the intracellular distribution pattern of cationic amphiphilic drugsMagdalena Vater, Leonhard Möckl, Vanessa Gormanns, et al.
Journal of Medicinal Chemistry|November 6, 2009
Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapyJesus M Ontoria, Sergio Altamura, Annalise Di Marco, et al.
Oncotarget|June 15, 2018
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemiaJoachim R Göthert, Roze Imsak, Michael Möllmann, et al.
Journal of Medicinal Chemistry|June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound designAndré Richters, Julia Ketzer, Matthäus Getlik, et al.
Angewandte Chemie (International Ed. in English)|January 21, 2017
A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2Pablo Martín-Gago, Eyad K Fansa, Christian H Klein, et al.
Journal of Medicinal Chemistry|August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor ReceptorJulian Engel, Steven Smith, Jonas Lategahn, et al.
Pageof 4